IP Library Granted Patent US 12,005,104
Granted Patent B2
US 12,005,104 · App. 17/263,290 · Granted Jun 11, 2024

Cancer vaccines for colorectal cancer

Inventor: Ronald Hans Anton Plasterk (Amsterdam, NL)
Assignee: CureVac Netherlands B.V.
A61K39/0011C12Q1/6886A61K2039/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,005,104
App. No.
17/263,290
Granted
Jun 11, 2024
Kind
B2
Abstract

The invention relates to the field of cancer, in particular colorectal cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the APC, ARID1A, KMT2D, RNF43, SOX9, TCF7L2, TP53, and ZFP36L2 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

Claims (13)

1. A therapeutic vaccine or collection of therapeutic vaccines for treating colorectal cancer comprising:

a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:709, an amino acid sequence having 90% identity to SEQ ID NO:709, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:709, or one or more nucleic acids encoding said peptide or collection of tiled peptides; and

a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:710, an amino acid sequence having 90% identity to SEQ ID NO:710, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:710, or one or more nucleic acids encoding said peptide or collection of tiled peptides; preferably also comprising

a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:711, an amino acid sequence having 90% identity to SEQ ID NO:711, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:711, or one or more nucleic acids encoding said peptide or collection of tiled peptides; and/or

a peptide, or a collection of tiled peptides, having the amino acid sequence selected from SEQ ID NO:712, an amino acid sequence having 90% identity to SEQ ID NO:712, a fragment comprising at least 10 consecutive amino acids of SEQ ID NO:712, or one or more nucleic acids encoding said peptide or collection of tiled peptides.

2. The therapeutic vaccine or collection of therapeutic vaccines of claim 1 , wherein at least two of said peptides are linked.

3. The therapeutic vaccine or collection of therapeutic vaccines of 2, wherein said peptides are comprised within the same polypeptide.

4. The therapeutic vaccine or collection of therapeutic vaccines of claim 1 , wherein the nucleic acid molecules encoding said peptides are comprised in one or more vectors.

5. The therapeutic vaccine or collection of therapeutic vaccines of claim 4 , wherein said vector is a viral vector.

6. The therapeutic vaccine or collection of therapeutic vaccines of claim 1 , further comprising a pharmaceutically acceptable excipient, an adjuvant, or a therapeutic agent.

7. The therapeutic vaccine or collection of therapeutic vaccines of claim 6 , wherein the therapeutic agent is a checkpoint inhibitor, a chemotherapeutic agent, or an antibody.

8. The therapeutic vaccine or collection of therapeutic vaccines of claim 6 , further comprising an immune-effective amount of adjuvant.

9. A method of treating an individual for colorectal cancer, the method comprising administering to the individual in need thereof a therapeutic vaccine selected from the therapeutic vaccine or collection of therapeutic vaccines of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Jul 20, 2022
From: FRAME PHARMACEUTICALS B.V.
To: CUREVAC NETHERLANDS B.V.
Reel/Frame 060776/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: PLASTERK, RONALD HANS ANTON
To: FRAME PHARMACEUTICALS B.V.
Reel/Frame 055232/0810 →
Priority Claims (3)
NL 2021400 · Jul 26, 2018 · national
NL 2022447 · Jan 24, 2019 · national
EP 19167600 · Apr 5, 2019 · regional
Continuity (1)
Related Publication 20210213117A1 · Jul 15, 2021